Accepting nucleoside (acid) an

United States in a study report, nucleoside (acid) common in patients with chronic hepatitis b Virology breakthrough in analogue, but almost 40% were not caused by virus-resistant, enhancing patients ' compliance and detect if confirmed for Virology breakthroughs and (or) of genotypic resistance to avoid unnecessary dressing change. Papers published: Hepatology [Hepatology 2011,53 (the 6): 1854].the research into 148 cases application nuclear Glycoside (acid) similar property treatment of chronic hepatitis b patients, which male 73%, average age 44.9 age, in follow-up during (37.5±20.1 a months), has 39 cases (26%) patients occurred at least 1 times of virus learn breakthrough, in this 39 cases patients in the, 15 cases (38%) again detection failed to confirmed virus learn breakthrough, and this 15 cases in the of 10 cases no gene type resistance drug of evidence. At the 5 years of treatment, virology breakthrough, was confirmed as virus science breakthroughs and the cumulative incidence of drug-resistant genotypes, 46.1% and 33.9%, respectively. % More than 9 Multivariable analysis showed that the HBV DNA cannot meet the detection limit is the only factor associated with virological breakthrough significantly. 10 patients with viral breakthrough but again could not be confirmed as Virology breakthrough or genotypic drug resistance in patients with maintained the antiviral treatment, all 10 cases decline in serum in patients with HBV DNA, of which 9 in an average of 6.8 months after got HBV DNA not detected. Continued follow-up period, 4 patients keep HBV DNA is not detected, 6 cases of HBV DNA in patients with transient rise, but there were no drug resistance genotype. www.cmt.com.cn